Aehr Test Systems
AEHR
$134.06
+8.73%
Aehr Test Systems designs, manufactures, and sells advanced test and burn-in systems for logic, optical, and memory integrated circuits, primarily serving the semiconductor manufacturing industry. The company is a niche player in the semiconductor test equipment market, with a focus on high-reliability applications such as automotive and, more recently, AI processors. The current investor narrative centers on Aehr's strategic pivot from electric vehicle (EV) applications to AI processor testing, which has driven record bookings and a surge in stock price, with revenue expected to triple next year. The company's recent quarterly results and news headlines highlight its growing role in the AI infrastructure build-out, making it a high-momentum, high-volatility small-cap story.…
AEHR
Aehr Test Systems
$134.06
Related headlines
Investment Opinion: Should I buy AEHR Today?
Based on the analysis, I rate AEHR as a Hold. The company has a compelling growth narrative with record bookings and a revenue inflection, but the extreme valuation and negative free cash flow warrant caution. The analyst consensus is mixed, with an average target of $115, implying 15.3% upside, but the limited coverage and high volatility suggest a balanced risk-reward profile.
Sign up to view all
AEHR 12-Month Price Forecast
The AI-driven growth story is compelling, with tangible evidence of accelerating revenue and bookings. However, the extreme valuation and negative free cash flow introduce significant risk. I would upgrade my stance to high confidence if the company demonstrates sustained profitability and positive free cash flow in the next two quarters. Conversely, I would downgrade to neutral if revenue growth decelerates or if the stock's valuation becomes even more stretched.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Aehr Test Systems's 12-month outlook, with a consensus price target around $115.00 and implied upside of -14.2% versus the current price.
Average Target
$115.00
0 analysts
Implied Upside
-14.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$110 - $125
Analyst target range
Analyst coverage is limited, with only 3 analysts providing ratings and price targets. The consensus recommendation is 'none' (no clear buy/sell consensus), but the average target price is $115.00, implying a 15.3% upside from the current price of $99.74. The target range is $110.00 to $125.00, with the high target suggesting a 25.3% upside and the low target a 10.3% upside. The narrow spread between the low and high targets (13.6%) indicates relatively high conviction among the few covering analysts. Recent institutional ratings show a mix of Hold and Outperform actions, with William Blair upgrading from Market Perform to Outperform in March 2026, while Freedom Broker and Craig-Hallum maintain Hold ratings. The limited coverage and mixed sentiment suggest that the stock is still under-followed relative to its market cap, which could lead to higher volatility and less efficient price discovery.
Bulls vs Bears: AEHR Investment Factors
Aehr Test Systems presents a compelling growth story driven by its successful pivot to AI processor testing, evidenced by record bookings and a strong revenue inflection. However, the stock's extreme valuation, negative free cash flow, and high volatility create significant downside risks. Currently, the bull case has stronger evidence given the tangible momentum in bookings and revenue, but the single most important tension is whether the company can sustain its growth trajectory to justify the premium valuation. If AI-related demand continues to accelerate and the company delivers on its revenue projections, the stock could re-rate higher; conversely, any miss could lead to a sharp correction.
Bullish
- AI pivot driving record bookings: Aehr's strategic shift from EV to AI processor testing has generated $37.2 million in new bookings in Q3 FY2026, a record that signals strong future demand. This pivot is directly aligned with the booming AI infrastructure build-out, as highlighted in recent news coverage.
- Revenue inflection in Q4 FY2026: Q4 FY2026 revenue surged 40.2% year-over-year to $19.75 million, reversing three consecutive quarters of decline. This inflection marks the beginning of the expected growth acceleration, with analyst consensus projecting revenue to nearly triple to $196.1 million next fiscal year.
- Return to profitability: Aehr posted net income of $1.39 million in Q4 FY2026, a sharp turnaround from losses of -$2.08 million, -$3.23 million, and -$3.20 million in the prior three quarters. This demonstrates the operating leverage potential as revenue scales.
- Strong balance sheet with low debt: The company holds $116.5 million in cash with a current ratio of 10.3 and a debt-to-equity ratio of just 0.045. This financial strength provides ample runway to fund growth initiatives without significant financial risk.
Bearish
- Extreme valuation premium: Aehr trades at a P/S ratio of 56.6x, over 500% above the semiconductor industry average of 5-10x. This valuation leaves virtually no room for error, as any growth disappointment could trigger a severe de-rating.
- Negative free cash flow: Trailing twelve-month free cash flow is -$5.38 million, indicating the company is still burning cash despite recent profitability. This reliance on external funding, including $79.9 million raised in Q4 FY2026, could dilute shareholders.
- Erratic revenue history: Revenue declined for three consecutive quarters before the Q4 FY2026 rebound, highlighting the lumpy nature of the business. This volatility makes it difficult to rely on consistent growth, and the AI-driven surge may not be sustainable.
- High volatility and beta: With a beta of 3.09, the stock is roughly three times more volatile than the market, and it has experienced a max drawdown of -43.9% over the past year. This makes it a risky holding for risk-averse investors, especially given the recent pullback from the 52-week high.
AEHR Technical Analysis
Aehr Test Systems is in a powerful sustained uptrend, with the stock up 448.6% over the past year, dramatically outperforming the S&P 500's 21.5% gain. The current price of $99.74 sits at 74.5% of its 52-week range (low of $16.38, high of $126.62), indicating the stock is trading closer to its highs but has pulled back from the peak. This positioning suggests strong momentum but also potential overextension, as the stock has experienced significant volatility, with a beta of 3.09, implying it is roughly three times more volatile than the market.
Beta
3.09
3.09x market volatility
Max Drawdown
-43.9%
Largest decline past year
52-Week Range
$16-$147
Price range past year
Annual Return
+610.8%
Cumulative gain past year
| Period | AEHR Return | S&P 500 |
|---|---|---|
| 1m | +52.7% | +2.9% |
| 3m | +34.7% | +5.0% |
| 6m | +364.8% | +13.9% |
| 1y | +610.8% | +20.4% |
| ytd | +505.0% | +13.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AEHR Fundamental Analysis
Revenue growth has been erratic but recently turned positive, with the latest quarter (Q4 FY2026, ended May 29, 2026) showing revenue of $19.75 million, a 40.2% year-over-year increase. This follows three consecutive quarters of revenue decline, with Q1, Q2, and Q3 FY2026 revenues of $10.97 million, $9.88 million, and $10.31 million, respectively. The growth inflection is driven by a surge in bookings for AI-related testing systems, with the company reporting $37.2 million in new bookings in Q3 FY2026. The company returned to profitability in Q4 FY2026 with net income of $1.39 million, a significant improvement from the net losses of -$2.08 million, -$3.23 million, and -$3.20 million in the prior three quarters. Gross margin expanded to 40.6% in Q4 FY2026 from 32.7% in Q3 FY2026, though it remains below the 50%+ levels seen in earlier periods. Aehr's balance sheet is solid, with a current ratio of 10.3, a debt-to-equity ratio of 0.045, and cash of $116.5 million at the end of Q4 FY2026. However, free cash flow has been negative on a trailing twelve-month basis (-$5.38 million), and the company has relied on equity issuance, raising $79.9 million in Q4 FY2026, to fund operations and growth.
Quarterly Revenue
$19751000.0B
2026-05
Revenue YoY Growth
+40.2%
YoY Comparison
Gross Margin
40.6%
Latest Quarter
Free Cash Flow
$-5376000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AEHR Overvalued?
Given that Aehr's trailing twelve-month net income is negative (EPS of -$0.0025), the price-to-sales (P/S) ratio is the most appropriate valuation metric. The current P/S ratio of 56.6x is extremely elevated, reflecting the market's high expectations for future growth. The forward P/E ratio of 72.1x, based on estimated EPS of $1.14, implies that the market expects a dramatic earnings recovery, which is consistent with the analyst consensus revenue estimate of $196.1 million for the next fiscal year. Aehr's P/S ratio of 56.6x is significantly higher than the semiconductor industry average, which typically trades in the 5-10x range, representing a premium of over 500%. This premium is justified only if the company can sustain its growth trajectory and achieve the profitability implied by forward estimates. Historically, Aehr's P/S ratio has ranged from 11.2x to 143.4x over the past five years, with the current level near the higher end, indicating that the market is pricing in optimistic expectations.
PE
-401.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~168x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-232.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. Aehr's negative free cash flow of -$5.38 million TTM indicates the company is not yet self-sustaining, and it relied on $79.9 million in equity issuance in Q4 FY2026 to fund operations. The debt-to-equity ratio is low at 0.045, but the reliance on dilution could pressure EPS. Revenue concentration is a concern, as the pivot to AI testing means a few large customers could drive a significant portion of sales, leading to lumpy results. The gross margin of 40.6% in Q4 FY2026, while improved, remains below the 50%+ levels seen in earlier periods, suggesting potential pricing pressure or mix shifts.
FAQ
The key risks of holding AEHR are: 1) Financial risk: negative free cash flow of -$5.38 million TTM and reliance on equity issuance for funding, which could dilute shareholders. 2) Valuation risk: the P/S ratio of 56.6x leaves little margin of safety, and any growth slowdown could trigger a severe selloff. 3) Market risk: with a beta of 3.09, the stock is highly sensitive to market swings, and a tech sector correction could amplify losses. 4) Competitive risk: larger players like Teradyne and Advantest could enter the AI testing space, pressuring margins. The most severe risk is a failure to sustain AI-driven growth, which could lead to a 50% or more decline from current levels.
The 12-month forecast for AEHR is bullish but with significant uncertainty. In the base case (50% probability), the stock is expected to trade in the $110-$125 range, aligning with the analyst average target of $115. In the bull case (30% probability), the stock could reach $125-$150 if AI demand accelerates and the company exceeds expectations. In the bear case (20% probability), the stock could fall to $60-$90 if growth disappoints or market conditions deteriorate. The most likely scenario is the base case, assuming the company executes on its AI pivot and delivers revenue growth in line with estimates. However, the high valuation and volatility mean that the actual outcome could vary significantly.
AEHR is significantly overvalued based on traditional metrics. Its P/S ratio of 56.6x is over 500% higher than the semiconductor industry average of 5-10x, and its forward P/E of 72.1x implies extremely high growth expectations. The stock's valuation is justified only if the company can deliver on its projected revenue of $196.1 million next year, which would represent a tripling of revenue. Historically, AEHR's P/S ratio has ranged from 11.2x to 143.4x, and the current level is near the higher end, indicating that the market is pricing in optimistic scenarios. The valuation suggests that the market expects flawless execution, and any disappointment could lead to a sharp de-rating.
AEHR is a high-risk, high-reward stock that could be a good buy for aggressive investors with a long-term horizon. The company has demonstrated strong momentum with a 40.2% revenue increase in Q4 FY2026 and record bookings of $37.2 million, indicating robust demand for its AI testing solutions. However, the stock trades at a P/S ratio of 56.6x, which is extremely expensive and leaves little room for error. The average analyst target of $115 implies a 15.3% upside, but the high volatility (beta of 3.09) means significant downside risk. It is a good buy only if you believe the AI-driven growth will continue and are willing to tolerate potential drawdowns of 40% or more.
AEHR is more suitable for long-term investment, but only for investors with a high risk tolerance. The company is in a growth phase with a promising AI testing niche, but its earnings are volatile, and it has a beta of 3.09, making it unsuitable for short-term trading unless you are an active trader. The stock has no dividend, so returns depend entirely on capital appreciation. Given the extreme valuation, a long-term horizon of at least 3-5 years is recommended to allow the growth story to play out and to ride out volatility. Short-term traders could profit from momentum, but the risk of sharp pullbacks is high, as evidenced by the -43.9% max drawdown over the past year.